>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • CNC +2.5% (guidance)
Other news:
  • TRVI +45.8% (Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough)
  • DBVT +15.8% (confirms alignment with FDA for Viaskin Peanut Patch)
  • TELO +11.8% (entered into a Stock Purchase Agreement with a certain accredited investor)
  • BTDR +8.6% (files $1.0 bln mixed shelf)
  • TSQ +6.4% (authorized to repurchase up to $50 million of the Company's issued and outstanding Class A common stock)
  • ELTX +6.4% (Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024)
  • ZNTL +4.9% (announces key management appointments)
  • HCM +4.4% (receives Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO combination in certain lung cancer patients)
  • PHX +4.4% (initiates strategic alternatives process)
  • ATS +3.8% (announces normal course issuer bid)
  • DDD +3.6% (divests Geomagic Software Portfolio)
  • CSTL +3.1% (Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma)
  • FLXS +2.7% (approves $30 mln repurchase plan)
  • MGX +2.5% (Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference "RNA at the Bench and Bedside IV")
  • TATT +2.5% (signs 5-yer agreement with major North American cargo carrier worth $17 mln)
  • BLCO +2.2% (issues response to rumors of a potential sale)
  • KR +2.1% (approves new $7.5 bln repurchase plan)
  • OLN +1.5% (increases share repurchase authorization to $2.0 billion)
  • ARES +1% (expands access to private equity strategy)
  • MODG +1% (completed the sale of its mobile game subsidiary, World Golf Tour)
Analyst comments:
  • BA +1.6% (upgraded to Neutral from Sell at Northcoast)
  • KDP +1.2% (upgraded to Buy from Hold at Deutsche Bank)